Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Targeting metabolic-epigenetic regulation for lymphedema treatment
EF 2018-19
Résumé
Lymphedema is a disease of a damaged lymphatic system, a fluid drainage system that runs parallel to the blood circulatory system in the human body. The disease is associated with abnormal metabolism and metabolism-induced gene activity changes may have an important role in lymphedema development and progression.
Why and to whom the research is important: One in five cancer survivors will develop lymphedema as a side effect after surgery and/or radiation treatment. This disease causes a greater than 70-fold increased risk of infection and chance of developing of another lethal cancer. Lymphedema is incurable and there are currently no effective therapies.
Nature of the work: Cells break down nutrients, like sugars or proteins, to build chemicals that can modify gene activity without changing the genetic code (i.e. epigenetic changes). To understand how metabolism uses epigenetic modifications to produce lymphedema, high-throughput methods will be employed to profile epigenetic changes induced under lean and obese metabolic conditions, which have been associated with mild and severe lymphedema disease outcomes respectively. The importance of the gene activity changes in impacting lymphedema outcomes will be confirmed in cell and mouse experiments.
Anticipated outcomes: Epigenetic data will improve our understanding of the biological mechanisms contributing to this disease and help guide identification of new drugs to be used for lymphedema treatment.
How the research will contribute to the field: With more than 1 million new Canadian cancer survivors expected in the next decade, many people will be affected by lymphedema, a disease that causes poor quality of life and life-threatening medical complications. New and effective treatments for lymphedema are urgently needed to improve health outcomes, minimize harm to patients in the long-term, and reduce financial burdens on the health system from ongoing treatment for this incurable disease.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
396623
Name
Kwan Jennifer Y
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Targeting metabolic-epigenetic regulation for lymphedema treatment
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Drug Discovery; Epigenetics; Genetics; Lymphedema; Mouse Model; Pharmacogenomics; Radiation Oncology; Rna-Sequencing; Surgery; Whole Genome Bisulfite Sequencing
Abstract
Lymphedema is a disease of a damaged lymphatic system, a fluid drainage system that runs parallel to the blood circulatory system in the human body. The disease is associated with abnormal metabolism and metabolism-induced gene activity changes may have an important role in lymphedema development and progression.
Why and to whom the research is important: One in five cancer survivors will develop lymphedema as a side effect after surgery and/or radiation treatment. This disease causes a greater than 70-fold increased risk of infection and chance of developing of another lethal cancer. Lymphedema is incurable and there are currently no effective therapies.
Nature of the work: Cells break down nutrients, like sugars or proteins, to build chemicals that can modify gene activity without changing the genetic code (i.e. epigenetic changes). To understand how metabolism uses epigenetic modifications to produce lymphedema, high-throughput methods will be employed to profile epigenetic changes induced under lean and obese metabolic conditions, which have been associated with mild and severe lymphedema disease outcomes respectively. The importance of the gene activity changes in impacting lymphedema outcomes will be confirmed in cell and mouse experiments.
Anticipated outcomes: Epigenetic data will improve our understanding of the biological mechanisms contributing to this disease and help guide identification of new drugs to be used for lymphedema treatment.
How the research will contribute to the field: With more than 1 million new Canadian cancer survivors expected in the next decade, many people will be affected by lymphedema, a disease that causes poor quality of life and life-threatening medical complications. New and effective treatments for lymphedema are urgently needed to improve health outcomes, minimize harm to patients in the long-term, and reduce financial burdens on the health system from ongoing treatment for this incurable disease.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kwan, Jennifer Y
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~